SCOPYD: Hypovitaminosis D Prediction Score

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT02822651
Collaborator
(none)
2,592
1
1
13.9
186.1

Study Details

Study Description

Brief Summary

Vitamin D has effects on many tissues, and hypovitaminosis D is frequent. In a French survey conducted among 1587 adults, vitamin D insufficiency (<30ng/ml) has been reported in 80% of subjects, including 43% with moderate deficiency (<20ng/ml) and 5% with severe deficiency (<10ng/ml).

Because of the possible consequences of hypovitaminosis D (osteomalacia in adults…), the number of vitamin D determination has increased ten-fold since 2005 in France, reaching 4.5 million € in 2011, and with it the costs for health insurance. However, there is currently no consensus on the strategy for detection, diagnosis and treatment of hypovitaminosis D.

We propose to develop a predictive clinical score of hypovitaminosis D based on the accurate assessment of solar exposure, vitamin D intakes and hypovitaminosis D risk factors collected through a self-administered questionnaire.

Condition or Disease Intervention/Treatment Phase
  • Biological: Blood sampling
  • Other: self-administered questionnaire
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
2592 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
SCOPYD Study: Development of a Predictive Clinical Score of Hypovitaminosis D
Actual Study Start Date :
Sep 19, 2016
Actual Primary Completion Date :
Nov 17, 2017
Actual Study Completion Date :
Nov 17, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Vitamin D status

The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.

Biological: Blood sampling
Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.

Other: self-administered questionnaire
Patients will fill a self-administered questionnaire the day of inclusion

Outcome Measures

Primary Outcome Measures

  1. 25 (OH) vitamin D blood concentration [The day of inclusion]

    Vitamin D determination will be carried out for each center in a single laboratory by chemiluminescence technique. Vitamin D determination is the gold standard for the development and validation phases of the score. It will define the variables of the self-administered questionnaire to be included in the final score (development phase) and be the gold standard in the evaluation of the performance score (validation phase). The blood sample will be collected after the completion of the questionnaire, on the same day.

Secondary Outcome Measures

  1. Vitamin D concentration level [The day of inclusion]

    The ability of the score to classify adults in one of these three categories: Category 1 : Vitamin D sufficiency (≥30 ng/ml) Category 2 : Hypovitaminosis D between 30 and 10 ng/ml Vitamin D insufficiency (<30 ng/ml) Vitamin D deficiency (<20 ng/ml) Category 3 : Severe deficiency (<10 ng/ml)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women aged 18 to 70 years old
Exclusion Criteria:
  • Participation in a study related to vitamin D

  • Taking at least 80 000 IU vitamin D in the last 3 months as a single dose

  • Pregnancy or breast-feeding

  • Renal failure : severe renal impairment, dialysis, having kidney transplant

  • Known hepatic impairment

  • Gastrointestinal disorders: Celiac disease, Crohn's disease, ulcerative colitis, bariatric surgery, gastrointestinal surgery with stoma

  • Known primary hypo/hyperparathyroidism

  • Bone cancer/metastases current or in the last 2 years

  • Treatment with antiepileptics

  • Long-term treatment with glucocorticoids (> 3 months)

  • Treatment with antiretroviral

  • Legal incapacity or limited legal capacity

  • Non-recipient of French Social Security

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices Civils de Lyon - Pôle IMER Lyon Cedex 03 France 69424

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Anne-Marie SCHOTT-PETHELAZ, MD, PhD, Hospices Civils de Lyon - Pôle d'Information Médicale et d'Evaluation de la Recherche

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT02822651
Other Study ID Numbers:
  • 69HCL15_0078
First Posted:
Jul 4, 2016
Last Update Posted:
Dec 21, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 21, 2018